JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Current evidence and emerging drug therapies for overactive bladder.

Overactive bladder is a common symptom complex with health related quality of life impacts on the individual as well as utilizing health resources. Antimuscarinic therapy has been the mainstay of treatment and is well supported within the literature and guidelines. However, compliance is poor due to lack of efficacy and adverse events leading to the development of novel therapies. Mirabegron, the B3-adrenoreceptor agonist has emerged as an evidence-based alternative first or second line therapy. Two decades after its first clinical application for overactive bladder, intravesical botulinum toxin is now an important part of any clinician's armamentarium for refractory cases. Despite these therapeutic options many patients find therapies ineffective or have adverse events. This has resulted in ongoing developments in the understanding of overactive bladder, potential new drugs and combination therapies, which this paper intends to review.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app